Sight Sciences FY2026 Earnings Forecast Cut by HC Wainwright

Sight Sciences, Inc. (NASDAQ:SGHT) – HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Sight Sciences in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.45) per share for the year, down from their prior estimate of ($0.40). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Sight Sciences’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Sight Sciences’ Q4 2026 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.20) EPS.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). Sight Sciences had a negative return on equity of 42.41% and a negative net margin of 32.13%. The business had revenue of $24.92 million during the quarter, compared to the consensus estimate of $23.55 million.

SGHT has been the topic of several other reports. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up from $9.00) on shares of Sight Sciences in a research note on Thursday, November 5th. Citigroup boosted their price objective on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, October 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research note on Wednesday, November 4th. Finally, UBS Group upped their price objective on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.62.

Sight Sciences Stock Performance

Shares of NASDAQ SGHT opened at $11.01 on Monday. The firm has a 50 day moving average of $8.77 and a 200 day moving average of $6.11. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $606.54 million, a price-to-earnings ratio of -21.17 and a beta of 2.44. Sight Sciences has a 12-month low of $3.38 and a 12-month high of $11.16.

Institutional Investors Weigh In On Sight Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd grew its position in shares of Sight Sciences by 20.7% during the third quarter. R Squared Ltd now owns 19,759 shares of the company’s stock worth $185,000 after purchasing an additional 3,388 shares in the last quarter. Diversified Trust Co lifted its holdings in Sight Sciences by 27.3% in the 3rd quarter. Diversified Trust Co now owns 18,989 shares of the company’s stock worth $178,000 after purchasing an additional 4,068 shares in the last quarter. Conquis Financial LLC bought a new position in Sight Sciences in the 2nd quarter worth approximately $27,000. WealthTrust Asset Management LLC boosted its stake in Sight Sciences by 14.1% in the 1st quarter. WealthTrust Asset Management LLC now owns 44,635 shares of the company’s stock worth $168,000 after purchasing an additional 5,529 shares during the period. Finally, Algert Global LLC boosted its stake in Sight Sciences by 25.3% in the 2nd quarter. Algert Global LLC now owns 28,266 shares of the company’s stock worth $153,000 after purchasing an additional 5,706 shares during the period. 55.51% of the stock is owned by institutional investors.

Insider Activity

In other news, CTO David Badawi sold 7,797 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the sale, the chief technology officer directly owned 1,975,075 shares in the company, valued at $17,874,428.75. This trade represents a 0.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Rodberg sold 7,208 shares of Sight Sciences stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $63,790.80. Following the transaction, the chief financial officer owned 216,829 shares in the company, valued at approximately $1,918,936.65. This trade represents a 3.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,646 shares of company stock worth $429,157 in the last quarter. 30.40% of the stock is currently owned by insiders.

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.